Literature DB >> 30734420

Breast cancer subtypes affect the nodal response after neoadjuvant chemotherapy in locally advanced breast cancer: Are we ready to endorse axillary conservation?

Bruna Cerbelli1, Andrea Botticelli2, Annalinda Pisano1, Domenico Campagna3, Ludovica De Vincentiis1, Angelina Pernazza1, Federico Frusone4, Paola Scavina5, Massimo Monti4, Lucio Fortunato6, Leopoldo Costarelli3, Giulia d'Amati1.   

Abstract

We evaluated the impact of breast cancer subtypes on pathologic complete response (pCR) in 181 patients with positive nodes undergoing neoadjuvant chemotherapy (NAC). After NAC, patients underwent surgery, with sentinel lymph node biopsy (SLNB) or axillary dissection (ALND). In 28.2% of cases a pCR was achieved, with the highest rate in Her2+ and triple negative tumors. Overall, nodal pCR was more frequent than breast pCR (P = 0.003) with higher percentages in Her2+ and LLB-Her2+ (P < 0.05). In the Her2+ group, nodal pCR was observed only with breast pCR. Thus, in Her2+ tumors, breast pCR predicts node pCR, supporting the use of SLNB in this subgroup to stage the axilla avoiding ALND.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  axillary surgery; breast cancer; lymph node surgery; neoadjuvant chemotherapy; pathologic complete response; tumour subtype

Mesh:

Substances:

Year:  2019        PMID: 30734420     DOI: 10.1111/tbj.13206

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  4 in total

1.  Axillary Response to Neoadjuvant Therapy in Node-Positive, Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Patients: Predictors and Oncologic Outcomes.

Authors:  Orli Friedman-Eldar; Tolga Ozmen; Salah James El Haddi; Neha Goel; Youley Tjendra; Susan B Kesmodel; Mecker G Moller; Dido Franceschi; Christina Layton; Eli Avisar
Journal:  Ann Surg Oncol       Date:  2022-03-18       Impact factor: 5.344

2.  Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.

Authors:  Z Fan; T Ouyang; L Wang; Y Li; J Li; T Wang; Y Xie; Y He
Journal:  Clin Transl Oncol       Date:  2020-06-09       Impact factor: 3.405

3.  Pathological examination of breast cancer samples before and after neoadjuvant therapy: recommendations from the Italian Group for the Study of Breast Pathology - Italian Society of Pathology (GIPaM-SIAPeC).

Authors:  Nicola Fusco; Antonio Rizzo; Leopoldo Costarelli; Alfredo Santinelli; Bruna Cerbelli; Cristian Scatena; Ettore Macrì; Francesca Pietribiasi; Giulia d'Amati; Anna Sapino; Isabella Castellano
Journal:  Pathologica       Date:  2022-04-13

4.  Addition of carboplatin-gemcitabine as second-line neoadjuvant chemotherapy in non-responsive locally advanced breast cancer patients to standard neoadjuvant chemotherapy and evaluation of factors affecting response: a randomized controlled trial.

Authors:  Dena Firouzabadi; Amirreza Dehghanian; Alireza Rezvani; Laleh Mahmoudi; Abdolrasoul Talei
Journal:  BMC Cancer       Date:  2021-01-11       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.